CAMP4 enters collaboration with GSK for ASO therapeutics; $17.5M upfront, up to $440M milestones

Camp4 Therapeutics Corp

Collaboration with GSK to discover ASO therapeutics for neurodegenerative and kidney diseases using CAMP4's RAP Platform.
CAMP4 receives $17.5M upfront; eligible for up to $440M in milestone payments plus tiered royalties.
CAMP4 performs research to identify and deliver lead ASO series; GSK responsible for development and commercialization.
Tiered royalties on annual net sales range from low- to mid-single digits; royalty term per product defined.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Camp4 Therapeutics Corp entered into Research, Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited valued at $17.5 million (effective 2025-12-17).

Action: entry
Agreement: collaboration
Counterparty: GlaxoSmithKline Intellectual Property (No. 3) Limited
Value: $17.5 million
Effective: 2025-12-17

Exact text from the filing

On December 17, 2025, CAMP4 Therapeutics Corporation (the “Company”) entered into a Research, Collaboration and License Agreement (the “Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”).

View on SEC.gov

803 material agreements filed in the last 30 days. Browse all material agreements →

Camp4 Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001736730-25-000111

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.